G
Guy W. Neff
Researcher at University of Cincinnati
Publications - 121
Citations - 4458
Guy W. Neff is an academic researcher from University of Cincinnati. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 33, co-authored 105 publications receiving 3860 citations. Previous affiliations of Guy W. Neff include University of Miami & Northeast Ohio Medical University.
Papers
More filters
Journal ArticleDOI
Rifaximin treatment in hepatic encephalopathy.
Nathan M. Bass,Kevin D. Mullen,Arun J. Sanyal,Fred Poordad,Guy W. Neff,Carroll B. Leevy,Samuel H. Sigal,Muhammad Y. Sheikh,Kimberly Beavers,Todd Frederick,Lewis W. Teperman,Donald J. Hillebrand,Shirley Huang,Kunal Merchant,Audrey L. Shaw,Enoch Bortey,William P. Forbes +16 more
TL;DR: Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopathy more effectively than did placebo, and also significantly reduced the risk of hospitalization involving hepaticEncephalopathy.
Journal ArticleDOI
Survival of Human Immunodeficiency Virus–Infected Liver Transplant Recipients
Margaret V. Ragni,Steven H. Belle,KyungAh Im,Guy W. Neff,Michelle E. Roland,Peter G. Stock,Nigel Heaton,Abhi Humar,John F. Fung +8 more
TL;DR: It is suggested that survival of HIV-positive liver transplant recipients does not differ from that ofAIDS-negative liver transplant recipient, and HIV infection should no longer be a contraindication to OLTX.
Journal ArticleDOI
Orthotopic liver transplantation in patients with human immunodeficiency virus and end‐stage liver disease
Guy W. Neff,Andrew Bonham,Andreas G. Tzakis,Margaret V. Ragni,Dushyantha Jayaweera,Eugene R. Schiff,Obaid Shakil,John J. Fung +7 more
TL;DR: Evaluated patients undergoing OLT with HIV under HAART therapy suggest that OLT is effective in selected HIV‐positive patients suffering from ESLD, and careful monitoring, and attention is required to prevent toxicity or underdosing.
Journal ArticleDOI
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison,Stephen A. Harrison,Guy W. Neff,Cynthia D. Guy,Mustafa R. Bashir,Angelo H. Paredes,Juan P. Frias,Ziad Younes,James F. Trotter,Nadege Gunn,Sam E. Moussa,Anita Kohli,Kristin Nelson,Mildred Gottwald,William C.G. Chang,Andrew Yan,Alex M. DePaoli,Lei Ling,Hsiao D. Lieu +18 more
TL;DR: In a phase 2 trial of patients with NASH, aldafermin reduced liver fat and produced a trend toward fibrosis improvement, and caused a decline in levels of 7alpha-hydroxy-4-cholesten-3-one, bile acids, alanine and aspartate aminotransferases, and Pro-C3 than placebo.
Journal Article
The current economic burden of cirrhosis.
TL;DR: This paper highlights recent publications that evaluate the cost-effectiveness of strategies that prevent or treat the main causes of cirrhosis as well as publications that assess the impact of quality of life on the overall cost burden of the disease.